EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseLeitlinieOpen Access · CC BY 4.0

A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?

Michele Bartoletti, Essy Mozaffari, Alpesh N Amin iD, Yohei Doi iD, Paul Loubet iD, Christina G Rivera iD, Michael Roshon, Aaditya Rawal iD, Emily Kaiser, Maria Vutcovici Nicolae, Shuai Fu, Thomas F Oppelt iD und 3 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf111 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Michele Bartoletti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Milan, Italy. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Antiviral Agents, COVID-19 Drug Treatment, Alanine. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With progressive accumulation of knowledge on SARS-CoV-2 infection clinical management, treatment guidelines recommended several options including remdesivir, a broad-spectrum antiviral. Given the evolving nature of coronavirus disease 2019, capturing the totality of scientific evidence from clinical trials and observational studies is critical to inform clinical decision making. We conducted a systematic literature review with meta-analysis to summarize the effectiveness of remdesivir among hospitalized adults.

Methods

We systematically searched MEDLINE, Embase and Cochrane Library databases for interventional and observational studies examining remdesivir efficacy. A rigorous double-reviewer approach was used for source identification, screening, data extraction and risk of bias assessment. A hierarchical random-effects model meta-analysis was used, with subgroup analyses for randomized controlled trials (RCTs) and real-world (RW) studies.

Results

From January 2019 to December 2023 >18 000 sources were screened, and 122 unique studies were identified, reporting on 25 174 participants in RCTs and 1 279 859 in RW studies. Remdesivir significantly increased survival in the overall population (odds ratio, 0.69 [95% confidence interval, .55–.86]; P = .001] across SARS-CoV-2 variants and disease severity levels: no supplemental oxygen (0.81 [.75–.88]), low-flow oxygen (0.71 [.64–.79]), high-flow oxygen (0.87 [.83–.91]), and invasive mechanical ventilation (0.78 [.68–.90]). Rehospitalization risk was significantly reduced in patients receiving remdesivir (odds ratio, 0.72 [95% confidence interval, .64–.81]).

Conclusions

Our comprehensive systematic literature review, capturing the totality of evidence, showed a significant survival benefit among patients hospitalized for SARS-CoV-2 infection and receiving remdesivir, across all disease severity levels. To assure that healthcare providers are aware of and deploy evidence-based optimal care, recommendations should rely on both RCT and RW data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphateAntiviral AgentsCOVID-19 Drug TreatmentAlanineCOVID-19HumansHospitalizationSARS-CoV-2Treatment OutcomePractice Guidelines as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

COVID-19SARS-CoV-2effectivenessremdesivirtreatment guidelines

Substanzen

remdesivirAdenosine MonophosphateAntiviral AgentsAlanine

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Infectious Disease Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Medical Affairs, Gilead Sciences, Foster City, California, USA.
  • Division of Hospital Medicine & Palliative Medicine, University of California Irvine, Irvine, California, USA.
  • Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
  • Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Alpesh N Amin, Yohei Doi, Paul Loubet, Christina G Rivera, Aaditya Rawal, Thomas F Oppelt, Andre C Kalil

Förderung

  • Gilead Sciences

Zitieren

APA

Bartoletti, M., Mozaffari, E., Amin, A. N., Doi, Y., Loubet, P., Rivera, C. G., Roshon, M., Rawal, A., Kaiser, E., Vutcovici Nicolae, M., Fu, S., Oppelt, T. F., Chiang, M., Sax, P. E., & Kalil, A. C. (2025). A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf111

Vancouver

Bartoletti M, Mozaffari E, Amin AN, Doi Y, Loubet P, Rivera CG, et al. A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf111

BibTeX
@article{Bartoletti2025,
  author = {Bartoletti, Michele and Mozaffari, Essy and Amin, Alpesh N and Doi, Yohei and Loubet, Paul and Rivera, Christina G and Roshon, Michael and Rawal, Aaditya and Kaiser, Emily and Vutcovici Nicolae, Maria and Fu, Shuai and Oppelt, Thomas F and Chiang, Mel and Sax, Paul E and Kalil, Andre C},
  title = {A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf111}
}
Kostenlos starten →